Rabeprazole
Drug Category | Drug | IHD Dosing |
Administration Timing Around HD Session |
---|---|---|---|
Proton Pump Inhibitors | Rabeprazole | 20mg PO Q24H | Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
359.44 | N/A | 1-2 | Unchanged | 96.3 | N/A | N/A | N/A |
References:
- DrugBank [Online]. 2013 Feb 06 [cited 2013 Feb 06]; Available from: URL:http://www.drugbank.ca
- Keane WF, Swan SK, GRimes I, Humphries TJ. Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. J Clin Pharmacol 1999;39:927-33.
- Rabeprazole. In: Lexi-Drugs Online. Hudson (OH): Lexi-Comp, Inc,; [updated 02/06/13; accessed 02/06/13].